|
Pre-initiation of GXR treatmenta
|
Post-initiation of GXR treatmentb
|
|---|
| |
n
|
Improvement
|
No change
|
Worsening
|
|---|
|
General Physician Symptom Assessment, n (%)*c
|
|
Improvement
|
172
|
130 (75.6)
|
2 (1.2)
|
0 (0.0)
|
|
No change
|
74
|
37 (50.0)
|
9 (12.2)
|
1 (1.4)
|
|
Worsening
|
54
|
44 (81.5)
|
2 (3.7)
|
3 (5.6)
|
|
General Physician Functional Assessment, n (%)c
|
|
Homelife*
|
|
Improvement
|
132
|
102 (77.3)
|
4 (3.0)
|
1 (0.8)
|
|
No change
|
118
|
52 (44.1)
|
9 (7.6)
|
2 (1.7)
|
|
Worsening
|
48
|
34 (70.8)
|
9 (18.8)
|
1 (2.1)
|
|
School performance*
|
|
Improvement
|
161
|
111 (68.9)
|
3 (1.9)
|
0 (0.0)
|
|
No change
|
89
|
45 (50.6)
|
11 (12.4)
|
2 (2.2)
|
|
Worsening
|
44
|
33 (75.0)
|
5 (11.4)
|
2 (4.5)
|
- Exploratory subgroup analysis in a subgroup of patients who had received prior pharmacotherapy for ADHD
- ADHD attention-deficit/hyperactivity disorder, GXR guanfacine extended-release
- *P < 0.001, derived through extension of McNemar’s test (Bowker’s test)
- aOverall response to treatment regimen administered prior to GXR administration
- bThe best response registered while on treatment with GXR
- cPercentages were calculated using the corresponding categories under GXR treatment count as denominator; due to missing values, percentages in each category do not add up to 100%
